# COMP360

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/comp360
Canonical HTML page: https://getyourbrief.com/entity/comp360

## Timeline

- **2026**: Anticipated Data Readout — Expected primary endpoint results for the COMP005 Phase 3 trial in TRD.
- **2025-12-31**: Fiscal Year End — Closed 2025 with a strategic focus on regulatory filing preparations.
- **2025-Q3**: Therapist Training Milestone — Completed training for over 500 facilitators to support Phase 3 delivery protocols.
- **2025-Q1**: Phase 3 Expansion — Compass increased the number of active clinical sites for COMP006 to over 50 globally.

## Recent coverage (1 stories, network-wide)

### Compass Pathways Reports 2025 Results as Pivotal Phase 3 Data Looms
2026-03-24 15:41:41 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
Full story: https://gethealthbrief.com/story/compass-pathways-2025-financial-results-comp360

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.